Romosozumab (Evenity®) accepted for restricted use within NHS Scotland for treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Approval based on RCT which demonstrated romosozumab for 12 months, followed by an oral bisphosphonate, reduced the risk of fractures compared with an oral bisphosphonate alone.

Source:

Scottish Medicines Consortium